Viridian Therapeutics, Inc. (0K1R.L)

USD 12.48

(9.0%)

Long Term Debt Summary of Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc.'s latest annual long term debt in 2023 was 20.2 Million USD , up 334.98% from previous year.
Viridian Therapeutics, Inc.'s latest quarterly long term debt in 2024 Q2 was 17.48 Million USD , down -13.98% from previous quarter.
Viridian Therapeutics, Inc. reported annual long term debt of 4.64 Million USD in 2022, down 0.0% from previous year.
Viridian Therapeutics, Inc. reported annual long term debt of - USD in 2021, down 0.0% from previous year.
Viridian Therapeutics, Inc. reported quarterly long term debt of 17.48 Million USD for 2024 Q2, down -13.98% from previous quarter.
Viridian Therapeutics, Inc. reported quarterly long term debt of 4.7 Million USD for 2023 Q2, up 0.68% from previous quarter.

Annual Long Term Debt Chart of Viridian Therapeutics, Inc. (2023 - 2012)

Historical Annual Long Term Debt of Viridian Therapeutics, Inc. (2023 - 2012)

Year	Long Term Debt	Long Term Debt Growth
2023	20.2 Million USD	334.98%
2022	4.64 Million USD	0.0%
2021	- USD	0.0%
2020	- USD	-100.0%
2019	4.32 Million USD	-45.93%
2018	8 Million USD	-19.33%
2017	9.92 Million USD	251.84%
2016	2.82 Million USD	-39.55%
2015	4.66 Million USD	0.0%
2014	- USD	0.0%
2013	- USD	-100.0%
2012	42.04 Thousand USD	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q1	20.32 Million USD	0.61%
2024 Q2	17.48 Million USD	-13.98%
2023 Q2	4.7 Million USD	0.68%
2023 Q3	20 Million USD	324.72%
2023 Q4	20.2 Million USD	1.03%
2023 FY	20.2 Million USD	334.98%
2023 Q1	4.67 Million USD	0.69%
2022 Q1	1.06 Million USD	0.0%
2022 Q3	4.61 Million USD	0.61%
2022 Q2	4.58 Million USD	332.55%
2022 Q4	4.64 Million USD	0.69%
2022 FY	4.64 Million USD	0.0%
2021 Q1	33 Thousand USD	0.0%
2021 Q3	1.1 Million USD	-5.74%
2021 Q4	- USD	-100.0%
2021 FY	- USD	0.0%
2021 Q2	1.16 Million USD	3436.36%
2020 Q1	3.38 Million USD	-21.7%
2020 Q2	5.38 Million USD	58.75%
2020 FY	- USD	-100.0%
2020 Q4	- USD	-100.0%
2020 Q3	4.12 Million USD	-23.29%
2019 Q2	6.18 Million USD	-12.86%
2019 FY	4.32 Million USD	-45.93%
2019 Q4	4.32 Million USD	-17.7%
2019 Q3	5.25 Million USD	-14.92%
2019 Q1	7.09 Million USD	-11.38%
2018 FY	8 Million USD	-19.33%
2018 Q1	10.01 Million USD	0.97%
2018 Q3	8.91 Million USD	-9.24%
2018 Q4	8 Million USD	-10.21%
2018 Q2	9.82 Million USD	-1.96%
2017 Q1	2.34 Million USD	-16.77%
2017 FY	9.92 Million USD	251.84%
2017 Q4	9.92 Million USD	613.3%
2017 Q3	1.39 Million USD	-25.65%
2017 Q2	1.87 Million USD	-20.28%
2016 Q3	3.29 Million USD	0.0%
2016 Q4	2.82 Million USD	-14.36%
2016 Q2	- USD	0.0%
2016 Q1	- USD	-100.0%
2016 FY	2.82 Million USD	-39.55%
2015 Q4	4.66 Million USD	0.0%
2015 Q1	- USD	0.0%
2015 FY	4.66 Million USD	0.0%
2015 Q3	- USD	0.0%
2015 Q2	- USD	0.0%
2014 Q4	- USD	0.0%
2014 Q1	- USD	0.0%
2014 Q2	- USD	0.0%
2014 Q3	- USD	0.0%
2014 FY	- USD	0.0%
2013 Q4	- USD	0.0%
2013 FY	- USD	-100.0%
2012 FY	42.04 Thousand USD	0.0%

Peer Long Term Debt Comparison of Viridian Therapeutics, Inc.

Name	Long Term Debt	Long Term Debt Difference
Xeris Biopharma Holdings, Inc.	190.93 Million USD	89.418%
Arrowhead Pharmaceuticals, Inc.	104.6 Million USD	80.685%
Codexis, Inc.	12.24 Million USD	-65.033%
Organovo Holdings, Inc.	888 Thousand USD	-2175.338%